TPIV200/huFR-1: Phase II started

TapImmune began an open-label, U.S. Phase II trial to evaluate 2 dose levels of intradermal TPIV 200 with or without cyclophosphamide in about 80 patients with stage IIb or III TNBC. Patients will rec...